Objective: To discuss a new anticoagulant drug to be used to prevent Stroke in Atrial Fibrillation patients and Venous Tromboembolism. Participants had to read some preliminary material prior to their participation.  


UK – London, Italy – Rome, Germany – Berlin



4 hour group discussion in central location with 8 participants per city (24 participants in total). Participant specialties per market:
1 PCT member
1 GP
1 or 2 secondary/ primary joint formularies members
1 or 2 regional HTA members
3 KOLs (2 in Stroke prevention in Atrial Fibrillation, 1 in Venous Tromboembolism treatment)

Solutions and Outcome

The project was a great success on all fronts. We recruited very strong candidates in all 3 cities and the outcome was excellent. The client was extremely satisfied.